Viking Therapeutics, Inc. - Common Stock (VKTX)
26.52
-1.65 (-5.86%)
NASDAQ · Last Trade: Jun 27th, 5:11 PM EDT
Detailed Quote
Previous Close | 28.17 |
---|---|
Open | 28.00 |
Bid | 26.57 |
Ask | 26.69 |
Day's Range | 26.20 - 28.09 |
52 Week Range | 18.92 - 81.73 |
Volume | 6,306,987 |
Market Cap | 2.64B |
PE Ratio (TTM) | -23.06 |
EPS (TTM) | -1.2 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 3,447,803 |
Chart
About Viking Therapeutics, Inc. - Common Stock (VKTX)
Viking Therapeutics is a biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders. The company is engaged in advancing a portfolio of drug candidates aimed at addressing diseases with significant unmet medical needs, including non-alcoholic steatohepatitis (NASH) and obesity. Viking’s approach leverages proprietary drug development technologies to design and optimize novel therapeutic compounds, with an emphasis on safety and efficacy. Through its research and clinical trials, the company aims to bring transformative treatments to market that can improve patient outcomes and enhance quality of life. Read More
News & Press Releases
The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss.
Via Investor's Business Daily · June 25, 2025
Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.
Via Benzinga · June 25, 2025
Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies.
Via Investor's Business Daily · June 23, 2025
Via The Motley Fool · June 21, 2025
Via The Motley Fool · June 18, 2025
Via The Motley Fool · June 16, 2025
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.
Via Investor's Business Daily · May 16, 2025
Via The Motley Fool · May 13, 2025
Via The Motley Fool · May 6, 2025
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.
Via The Motley Fool · May 2, 2025